

UNITED THERAPEUTICS CORP

Form 8-K

September 23, 2003

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15 (d) of the**  
**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 22, 2003

United Therapeutics Corporation

---

(Exact Name of Registrant as Specified in Charter)

---

Delaware

---

000-26301

---

52-1984749

(State or Other  
Jurisdiction of  
Incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification Number)

---

1110 Spring Street  
Silver Spring, MD

---

20910

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(301) 608-9292

---

**Item 5. Other Events.**

On September 22, 2003, United Therapeutics Corporation (the Company ) issued a press release announcing that the French Regulatory Agency has recommended that Remodulin not be approved in France based on insufficient demonstration of clinical efficacy for the claimed indication. A copy of the press release is attached hereto and incorporated herein by this reference.

**Item 7. Exhibits**

(c) Exhibits

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press release dated September 22, 2003

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: September 23, 2003

By: /s/ Paul A. Mahon  
Name: Paul A. Mahon  
Title: General Counsel

---

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
99.1	Press Release dated September 22, 2003